Sponsor Decision: The trial has been withdrawn with no plans to continue development.

The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.

Inclusion Criteria:

• Participants must have been diagnosed with relapsing MS

• Participants must have one of the following

  1. at least 1 documented relapse within the previous year, or
  2. at least 2 documented relapse within the previous 2 years, or
  3. at least 1 active Gd-enhancing brain lesion on an MRI scan in the past 6 months prior to screening.

Exclusion Criteria:

• Have had a diagnosis of primary progressive MS
• Have a history of another clinically significant neurological disease
• Had a relapse of MS within 30 days prior to randomization.

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.